GlassScriptPhysician profile
Kevin Liu
NPI 1437167046
$1,334.46
in general payments reported to CMS, 2019-2025
27 companies · $212 in 2025
The $212 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $122 · 2021: $19.02 · 2022: $83.74 · 2023: $310 · 2024: $305 · 2025: $212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $233.86 | 2019-2025 | |
| Inari Medical, INC. | $189.67 | 2019 | |
| Glaxosmithkline, LLC. | $145.14 | 2019-2025 | Shingrix, Arexvy |
| Idorsia Pharmaceuticals US INC | $74.75 | 2023-2024 | Quviviq |
| Novo Nordisk INC | $70.84 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $70.69 | 2024-2025 | Freestyle Libre 3 |
| Supernus Pharmaceuticals, INC. | $68.45 | 2020 | |
| Sanofi Pasteur INC. | $51.22 | 2023 | |
| Janssen Pharmaceuticals, INC | $45.21 | 2019-2023 | Xarelto |
| Dynavax Technologies Corporation | $41.08 | 2023-2024 | Heplisav-B |
| Sunovion Pharmaceuticals INC. | $39.17 | 2020 | |
| Astellas Pharma US INC | $33.10 | 2024 | Veozah |
| Astrazeneca Pharmaceuticals LP | $29.97 | 2024-2025 | Airsupra, Breztri |
| Sanofi-Aventis U.S. LLC | $25.93 | 2025 | |
| Merck Sharp & Dohme LLC | $22.21 | 2024 | Gardasil, Capvaxive, Gardasil 9 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.60 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $19.02 | 2021 | |
| Abbvie INC. | $18.66 | 2023 | |
| Seqirus USA INC | $16.57 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Dexcom, INC. | $16.41 | 2025 | Dexcom G6 Transmitter |
| Kaleo, INC. | $15.47 | 2022 | |
| Lilly USA, LLC | $15.38 | 2025 | Zepbound, Mounjaro |
| Eisai INC. | $15.29 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $15.29 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.71 | 2019 | |
| Aimmune Therapeutics, INC. | $13.52 | 2025 | Zenpep |
| Lundbeck LLC | $13.25 | 2024 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Liu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.